Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W
Proc Natl Acad Sci U S A. 2012 109 (31): E2127-33

PMID: 22773810 · PMCID: PMC3411967 · DOI:10.1073/pnas.1203530109

MeSH Terms (16)

Amino Acid Substitution Cell Line, Tumor Clinical Trials as Topic Drug Resistance, Neoplasm ErbB Receptors Female Humans Lung Neoplasms Male MAP Kinase Kinase 1 Mutation, Missense Protein Kinase Inhibitors Proto-Oncogene Proteins Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins p21(ras) ras Proteins

Connections (2)

This publication is referenced by other Labnodes entities: